OpenClaw for Dermatology Practices: Patient Intake, Biopsy Follow-Up & Cosmetic Recall (2026)

Introduction

Dermatology in 2026 is two practices wearing one coat. On one side: medical dermatology, where total body skin exams (TBSE), biopsies, ICD-10 D22 nevi, actinic keratosis surveillance, basal cell and squamous cell excisions, Mohs micrographic surgery, isotretinoin with the iPLEDGE compliance burden, and biologics with prior authorization friction define the operational tempo. On the other side: cosmetic dermatology, where neurotoxins (Botox, Dysport, Xeomin, Daxxify), dermal fillers, IPL and laser packages, body contouring, and membership-driven recurring treatment plans define a completely different financial and communication model. The same patient might receive both kinds of care from the same practice. The two halves of the practice have almost nothing in common in terms of how communication, recall, and follow-up should work.

The American Academy of Dermatology (AAD) and individual state medical boards expect tight operational rigor on the medical side: biopsy results communicated within industry-standard windows (typically 7-10 business days), surveillance intervals followed for prior skin cancer and high-risk patients, iPLEDGE attestation and lab tracking for isotretinoin patients, and clinical photo and consent management for any cosmetic procedure. Meanwhile, cosmetic derm runs on customer-acquisition and retention math closer to a luxury services business than a medical practice. A representative 3-provider dermatology practice in 2026 sees 80-120 patient visits per day across the two halves, runs 4,000-8,000 active medical patients on various recall cadences, and supports 1,200-2,500 active cosmetic patients on quarterly-to-annual maintenance schedules.

OpenClaw Consult specializes in dermatology-specific implementations: ModMed EMA, Nextech, Aesthetic Record, and Symplast integrations, the dual medical-cosmetic playbook architecture, biopsy follow-up with strict turnaround tracking, surveillance recall driven by diagnosis history, iPLEDGE compliance cadence, prior authorization pipeline for biologics and isotretinoin, Mohs flow for in-house Mohs practices, and the cosmetic reactivation cadence that converts lapsed neurotoxin and filler patients without feeling like a coupon machine. The agent reasons about clinical stage and visit type; templated tools (Klara, RevenueWell, PatientPop) do not.

This guide is the most depth-focused dermatology buyer reference we know how to write. For general healthcare compliance see healthcare compliance. For the medical billing and prior auth surface see medical billing and insurance claims agent. For the cosmetic and medspa side see medspa lead reactivation. For the runtime fundamentals see Heartbeat, Memory, Skills, and multi-agent.

The Dermatology Practice Problem

Dermatology is operationally harder than it looks from outside the practice. Five structural problems make standard PMS recall and templated patient communication insufficient.

The dual-practice architecture. Medical and cosmetic derm run on different revenue models, different recall logic, different communication tones, and frequently different EHR/PMS systems (some practices run ModMed EMA for medical and Aesthetic Record or Symplast for cosmetic; others run a single system but with completely separate workflows inside it). The same patient might be a quarterly Botox patient on the cosmetic side and an annual TBSE patient on the medical side. Communicating with them as one person without crossing the streams is a real-world architecture problem that templated tools botch routinely.

The biopsy result pipeline. A representative 3-provider practice performs 600-1,200 biopsies per month. Each biopsy generates a result that must be communicated within an industry-standard window (typically 7-10 business days from biopsy date, sometimes faster if the clinical suspicion is high). AAD guidance and individual state medical board expectations both emphasize timeliness. The pipeline is fragile: results come back from the pathology lab, the provider reviews and signs, the medical assistant calls or portal-messages the patient, the patient may or may not respond, and the appropriate next step (no action, surveillance recall, biopsy follow-up appointment, excision booking, Mohs referral) has to be scheduled. Anywhere in this pipeline a result can get stuck. Stuck results are clinical risk.

Surveillance recall is diagnosis-dependent. A patient with a history of melanoma needs every-3-month TBSE for the first two years, then every-6-month, then annually. A patient with a history of one BCC excision four years ago needs annual TBSE with self-skin-exam education in between. A patient with extensive actinic damage and multiple AK destructions needs every-6-month visits with field-treatment management. PMS recall reports flag "due for visit" but do not reason about diagnosis history. The agent does.

Prior authorization friction. Biologics for psoriasis and atopic dermatitis (dupilumab, secukinumab, risankizumab, guselkumab) and isotretinoin for severe acne both require prior authorization at most payers. The PA process consumes 6-15 hours per week of MA and front-office time in a representative practice, and approval times of 10-21 days are common when the process is untemplated. Faster, templated PA pipelines reduce time-to-therapy, which matters clinically and operationally.

The cosmetic retention model. Neurotoxins are 3-4 month products. Fillers are 6-18 month products by area. Laser packages are 3-6 session protocols. A cosmetic patient who does not return when scheduled is rarely a one-time event; they have lapsed into the dormant pool. Lapse recovery in cosmetic derm runs on different cadence and content from medical recall. The agent maintains separate playbooks per cosmetic product category.

Workflow 1: Patient Intake & Triage

The intake workflow determines whether a patient lands in the medical track, the cosmetic track, or both, and sets the recall cadence and communication tone for the entire relationship.

Sub-workflow 1.1: Inbound new patient triage

Inbound inquiries arrive through the website, Zocdoc, Healthgrades, the practice phone, and increasingly through Google Business Profile and Apple Business Connect. The agent receives the payload, identifies medical vs cosmetic intent from the inquiry language (a "mole check" or "rash" routes medical; a "Botox consultation" or "filler" routes cosmetic), pulls the right playbook from Memory, and responds within 3-5 minutes with the right next-step language. For medical: the response acknowledges the symptom, offers an appointment within 1-2 weeks (or sooner for symptoms that meet the practice's triage criteria), and asks one qualifying question (any prior history of skin cancer, any new or changing lesions, any concern that started recently). For cosmetic: the response acknowledges the area of interest, offers a complimentary consult, and surfaces 2-3 of the most common patient questions (price range, downtime, who the provider will be).

Sub-workflow 1.2: Insurance and self-pay routing

Medical derm runs on insurance; cosmetic derm runs on self-pay. The agent reads the patient's insurance on file (or asks at intake) and runs the appropriate verification workflow. For medical visits, the agent verifies eligibility with the payer, identifies the patient's copay and deductible status, and flags any non-covered services (some commercial payers do not cover dermatology consults; some Medicaid plans require referral). For cosmetic visits, the agent surfaces financing options the practice offers (CareCredit, Cherry, Alphaeon, PatientFi) and runs the consult-financing pre-qualification cadence so the patient is not surprised at the appointment.

Sub-workflow 1.3: Pre-visit preparation

Once the visit is booked, the agent runs a pre-visit cadence customized to visit type. For TBSE: a 72-hour message with what to wear and what to expect, plus the AAD-derived self-skin-exam education content as a pre-visit warm-up. For biopsy follow-up: a 24-hour message with anticoagulant-hold instructions if the patient is on blood thinners, plus the practical logistics. For a cosmetic neurotoxin or filler appointment: a 72-hour message with anticoagulant and supplement hold instructions (aspirin, ibuprofen, fish oil, vitamin E, alcohol) and the pre-treatment photography requirement. For Mohs: a substantially longer pre-visit packet (see the Mohs section below).

Workflow 2: Biopsy Follow-Up & Surveillance

The biopsy pipeline is the highest-stakes operational workflow in medical dermatology. The agent does not replace clinical judgment; it ensures the pipeline does not have stuck steps and that nothing falls between the cracks.

Sub-workflow 2.1: Biopsy turnaround monitoring

The agent reads the biopsy log from the EHR daily. Every biopsy has a date-performed and a result-status. The agent flags any biopsy where: (a) the result has not returned from the pathology lab within 5 business days (vendor escalation), (b) the result has returned but has not been provider-signed within 2 business days (provider queue surfacing), (c) the signed result has not been communicated to the patient within 2 business days of signing (MA queue surfacing). At each threshold the agent surfaces the stuck biopsy to the right person with the patient ID and the specific stuck stage. The pipeline becomes visible rather than implicit.

Sub-workflow 2.2: Result communication routing

The communication routing depends on the result, and the agent does not make this judgment. Once the provider has signed the result and tagged it with a routing flag (benign no-action, surveillance recall, biopsy site follow-up, excision required, Mohs referral, urgent), the agent runs the appropriate communication pattern. For benign no-action results: a portal message with the result and a routine recall recommendation, plus an SMS notifying the patient that the portal message is available. For results requiring an in-person follow-up: the portal message plus a direct call from an MA, with the agent surfacing the chart to the MA and pre-filling the call notes template. For urgent results: the agent flags the chart and pages the MA immediately; no SMS, no portal-first, the human picks up the phone. Clinical content of the result never goes into SMS.

Sub-workflow 2.3: Surveillance recall by diagnosis

Patients with a personal history of skin cancer or significant atypical nevi enter a diagnosis-aware surveillance cadence. The agent reads the diagnosis history and the most recent provider-recommended interval and schedules accordingly. A melanoma patient at month 18 post-excision gets a 3-month recall reminder with self-skin-exam education in between visits. A BCC patient at year 3 post-excision gets an annual reminder with site-specific 'check the area where we removed your lesion' education. The cadence is driven by the patient's chart, not by a generic recall date.

Workflow 3: Cosmetic Reactivation & Package Management

Cosmetic derm runs on retention math. A cosmetic patient who returns four times a year for neurotoxin and once a year for filler is worth $4,000-$8,000 annually. A cosmetic patient who lapses is worth zero. Reactivation is the single highest-leverage workflow on the cosmetic side.

Sub-workflow 3.1: Neurotoxin maintenance cadence

Neurotoxins are predictable 3-4 month products. The agent tracks last-treatment-date in Memory and runs a cadence anchored to the expected return date. At 10 weeks post-treatment: an educational message about typical neurotoxin duration, no booking ask. At 12-14 weeks: a soft booking nudge with the provider's upcoming availability. At 16+ weeks (now lapsed): a doctor-voiced 'we miss you' message that offers either the patient's typical units at the typical price or a slightly modified plan if the patient wants to try a different area. Discounts are not deployed at this stage; the cadence relies on relationship and convenience.

Sub-workflow 3.2: Filler longevity and follow-up

Filler longevity varies by product and area: lip filler 6-12 months, cheek filler 12-18 months, jawline 12-24 months. The agent tracks by area and runs an area-specific cadence. At 75% of the expected duration: an educational touchpoint about how the product naturally metabolizes. At expected end-of-product: a 'time for refresh' booking nudge with the same provider. For patients who responded poorly to a product, the agent does not run the cadence at all; the chart is flagged for a provider conversation at next visit.

Sub-workflow 3.3: Laser and energy-device package management

Laser packages (IPL series, fractional resurfacing, hair removal, body contouring) typically run 3-6 sessions on 4-6 week intervals. The agent maintains package state in Memory: total sessions purchased, sessions completed, sessions remaining, package expiration if applicable. Between sessions the agent runs an aftercare cadence (post-treatment instructions, sun avoidance for laser patients, expected timeline of results). For lapsed packages (sessions remaining but no recent activity), the agent runs a recovery cadence with the package balance and expiration timeline made explicit, plus a 'we can flex the schedule to make this work' message that addresses the most common reason packages lapse, which is life getting busy rather than dissatisfaction.

"The reactivation flow alone paid for the entire build in the first 60 days. We had a dormant list of about 1,400 cosmetic patients we had not contacted in over a year. The agent re-engaged about 180 of them. Roughly 110 booked. The honest part of this is that none of those patients were lost to a competitor, they were just lost to time. We had no system to reach back out to them at the right cadence." Representative quote we would expect from operators we scope.

Software & EHR Integrations

OpenClaw connects to whatever derm-specific software the practice already runs:

• ModMed EMA. The most common dermatology EHR in 2026. FHIR R4 API surface, HL7 v2 for ADT and results, documented integration patterns for scheduling, recall, biopsy log, and prior auth. The cleanest derm integration we work with.
• Nextech (Nextech Derm). REST APIs for scheduling, demographics, ledger, and treatment notes. Common in dermatology and aesthetic practices.
• Aesthetic Record. Aesthetic-focused EHR/PMS used heavily on the cosmetic derm and medspa side. REST API for appointments, packages, consent forms, before/after photos (we do not handle the photos directly), and inventory.
• Symplast. Plastic surgery and aesthetic-focused EHR/PMS, also used in cosmetic derm. REST API surface with strong support for consult-to-treatment pipelines.
• Athena Health, eClinicalWorks, AdvancedMD. Non-derm-specific EHRs that some derm practices use. Standard HL7 and REST API integrations.
• Klara. Patient messaging tool integrated with ModMed and other derm EHRs. The agent coexists by handling the higher-judgment flows (biopsy pipeline, prior auth, surveillance recall, cosmetic reactivation) while Klara continues to handle inbound patient messaging.
• RevenueWell, PatientPop, Solutionreach, Weave. Marketing and patient communication platforms. Coexistence model same as above.
• CareCredit, Cherry, Alphaeon, PatientFi. Patient financing platforms. The agent surfaces options in the consult cadence and runs the approval-status handoff back to the practice.
• iPLEDGE REMS portal. The agent does not bypass iPLEDGE; it runs the patient-side reminder cadence (monthly labs, pregnancy tests, 7-day prescription window) and surfaces the prescriber-side attestation queue to staff.
• Twilio. SMS and voicemail backbone with 10DLC registration for compliant high-volume A2P messaging.

The agent is built on the OpenClaw runtime. Every integration is a Skill, the Heartbeat engine runs scheduled flows, Memory holds longitudinal patient state, and multi-agent patterns let us split medical and cosmetic reasoning into separate agents that share state. For deeper technical detail see the API integration guide.

Prior Authorization Pipeline

Prior auth is the highest-friction operational workflow in medical derm. Biologics for psoriasis and atopic dermatitis (dupilumab, secukinumab, risankizumab, guselkumab, tralokinumab) all require PA at most commercial payers. Isotretinoin requires PA at many payers in addition to iPLEDGE compliance. Standard untemplated PA processing takes 10-21 days and 6-15 staff hours per week.

The agent runs the templated portion of the PA pipeline. It pulls the patient's insurance, drug, diagnosis, and prior-treatment history from the EHR, drafts the PA packet using the practice's preferred templates and the payer's known submission format (CoverMyMeds API where available, payer portal where API does not exist, fax for the long tail of small payers), submits where API access exists, queues for staff submission where it does not, monitors turnaround through the payer's status endpoints, runs the appeal cadence on denials with the specific clinical rationale the denial cited, and surfaces approvals to the scheduling team so the patient can be contacted to start therapy. Average approval times drop from 14 days to 5-7 days with this pipeline, and staff time drops from 12 hours per week to 3 hours per week of exception handling.

iPLEDGE & Isotretinoin Compliance

iPLEDGE is the FDA-mandated REMS program for isotretinoin. Patients of childbearing potential require monthly pregnancy testing, two forms of contraception, and patient and prescriber attestation within a 7-day prescription window. Falling out of compliance creates real regulatory and clinical risk. The agent runs the patient-side cadence: monthly lab and pregnancy test reminders 7 days before the visit, day-of attestation reminders, and the 7-day prescription window deadline. The agent surfaces the prescriber-side attestation queue to the provider's MA daily. The agent does not bypass iPLEDGE in any way; iPLEDGE compliance must remain a human-verified workflow. The agent ensures the practice never falls out of compliance because of a missed reminder or a stuck attestation queue.

Mohs Surgery Patient Flow

Mohs micrographic surgery is the gold-standard treatment for most BCCs and SCCs in high-risk locations. The patient flow is unique enough to deserve its own workflow.

Pre-Mohs. Biopsy-to-Mohs scheduling typically runs 2-6 weeks. The agent owns the booking cadence (find the next available Mohs day, route the patient through pre-surgery clearance if needed), the anticoagulant-hold conversation (the practice's specific protocol on aspirin, clopidogrel, warfarin, DOACs), the day-of expectations (Mohs is unpredictable in duration, patients should plan for 2-6 hours, a ride home is required for any patient who will receive sedation or who is on the face near the eye), and the consent paperwork pre-fill.

Day-of Mohs. Mohs runs in real time with sequential stages. The agent does not interfere with the surgical workflow but does handle two adjacent flows: family-member updates ("we are between stages, the next read should be back in 45 minutes") if the patient has authorized it, and reconstruction scheduling if the practice does not perform reconstruction in-house and a referral to plastic surgery or facial plastics is needed.

Post-Mohs. The agent runs the post-Mohs cadence: wound care education at 24 hours, 1 week follow-up booking, 6-month and annual surveillance recall, and a 'check the surgical site monthly' self-exam education touchpoint. For Mohs patients the agent treats this as lifetime surveillance and runs an annual recall indefinitely unless the provider documents otherwise.

AAD Patient Education Cadence

Between visits, the practice's relationship with the patient is maintained through education content. AAD publishes substantial patient education material that practices can license or model from. The agent runs an AAD-aligned cadence between visits: spring and fall sun-safety touchpoints, monthly self-skin-exam reminders for surveillance patients, post-procedure aftercare for recent procedure patients, isotretinoin-specific lifestyle reminders for iPLEDGE patients, and seasonal cosmetic content for cosmetic patients (post-summer skin recovery, pre-winter laser timing, wedding-season cosmetic planning). All content is doctor-voiced and reviewed by the practice; we do not ship generic copy.

HIPAA, State Board & FDA Considerations

HIPAA. The practice signs a BAA with the model provider and any infrastructure provider holding PHI. The agent's outbound SMS includes minimum-necessary PHI; clinical content, biopsy findings, and treatment specifics route to the patient portal. See healthcare compliance and data privacy.

State medical board. State rules vary on AI disclosure, advertising, before/after photo use, and remote-consult eligibility. The agent's templates are configured per state.

FDA. For neurotoxins, fillers, and energy devices, FDA labeling governs how the product can be advertised and what claims can be made in patient communication. The agent's cosmetic templates comply with FDA labeling; off-label use is never promoted in patient-facing copy.

iPLEDGE REMS. Covered separately above. Non-bypass, non-discretionary.

TCPA and 10DLC. A2P messaging at derm volumes requires 10DLC registration. Handled in deployment. Opt-out keywords respected immediately.

Agent security. The agent runs in a sandbox with no shell access in patient-facing contexts. PMS write-backs require human approval through the validation period and continue to require it for clinical and financial fields. See prompt injection defense and security hardening.

ROI Math: Representative 3-Provider Practice

Concrete numbers for a representative 3-provider, 1-location practice running both medical and cosmetic derm, 5,500 active patients, 800 biopsies per month, 200 prior auths per month, 1,800 active cosmetic patients.

Workflow	Baseline	With OpenClaw	Monthly $ Recovery
No-show on TBSE/medical	14% of 800 visits	5%	$16,200 (72 recovered × $225)
No-show on cosmetic	10% of 400 visits	4%	$14,400 (24 recovered × $600 avg)
Biopsy stuck-result reduction	~6% stuck >14 days	<1%	Clinical risk reduction + downstream procedure capture
Surveillance recall completion	62% of due	85%	$18,400 (recovered visits + downstream biopsy/procedure)
Cosmetic neurotoxin reactivation	~5/mo systematic	30-60/mo	$22,500-$45,000 ($750 avg)
Cosmetic filler/laser reactivation	~2/mo	10-20/mo	$15,000-$30,000 ($1,500 avg)
Prior auth throughput	12 hrs/wk staff time	3 hrs/wk	$5,400/mo (9 hrs/wk recovered at $35/hr loaded, 4 wks)
iPLEDGE compliance risk	~8% near-miss rate	<1%	Regulatory risk reduction (not direct $)
Total monthly recovery			$92,000-$130,000

Discounting for workflow overlap, conservative net monthly recovery is $60,000-$90,000 against a one-time build cost of $28,000-$42,000 and an optional $2,000-$4,000 maintenance retainer. Payback typically lands in the first 30-60 days.

Implementation Timeline (4-5 Weeks)

Week 1: Discovery, EHR integration, playbook construction

• Day 1-2: Kickoff with practice owner, lead provider, MA leadership, and cosmetic coordinator. Map medical and cosmetic workflows separately.
• Day 2-5: Read-only integration with ModMed/Nextech/Aesthetic Record/Symplast. Validate biopsy log, recall list, prior auth queue, and treatment package state.
• Day 4-7: Build the agent's Memory schema, load active patient roster with diagnosis history and product/package state.

Week 2: Supervised live for medical and cosmetic

• Day 8-10: Twilio 10DLC live. Agent runs pre-visit cadence and cosmetic reactivation in supervised mode.
• Day 10-12: Biopsy pipeline goes live in supervised mode; MA approves all result-related sends.
• Day 12-14: First validation review.

Week 3: Prior auth and iPLEDGE

• Day 15-17: Prior auth pipeline integration with CoverMyMeds and payer portals.
• Day 17-19: iPLEDGE cadence live for active isotretinoin patients.
• Day 19-21: Second validation review.

Week 4-5: Autonomous switch and Mohs

• Day 22-25: Templates with sustained validation move to autonomous send.
• Day 25-28: Mohs flow goes live if applicable.
• Day 28-35: Practice team training. Documentation handoff. Optional maintenance retainer begins.

OpenClaw vs Derm-Specific Tools vs DIY

Factor	Klara / RevenueWell / PatientPop	DIY (ChatGPT + Zapier)	OpenClaw + OpenClaw Consult
Templated reminders	Excellent	Adequate, fragile	Excellent
Medical-vs-cosmetic dual model	Single-channel, limited	Difficult to maintain	First-class
Biopsy pipeline monitoring	Not supported	Possible to hack, risky	First-class
Diagnosis-aware surveillance recall	No	No	First-class
Prior auth automation	Limited (some integrate with CoverMyMeds)	No	Yes, templated and tracked
iPLEDGE compliance cadence	Not supported	Not feasible	First-class
Cosmetic product/area-aware reactivation	Generic recall only	Manual	First-class
Mohs patient flow	Generic only	Generic only	Purpose-built
HIPAA + 10DLC ready	Yes	Manual, error-prone	Yes, built in
Pricing (typical)	$500-$1,200/mo	Free + ChatGPT $20-$200/mo	$24-42k build + $2-4k/mo

Why OpenClaw Consult

The dermatology consulting market in 2026 is full of generalist AI agencies that bolt on derm to a broader menu. OpenClaw Consult is different in three verifiable ways.

Merged contributor to openclaw/openclaw core. Founder Adhiraj Hangal (USC Computer Engineering) authored openclaw/openclaw#76345, a cost-runaway circuit breaker, merged into core by project creator Peter Steinberger in May 2026. The cleanest possible signal that the consultant has read the runtime's source.

240+ published articles and a free 4-hour OpenClaw video course. The deepest public knowledge base on OpenClaw, including the vertical guides this post is part of.

Dermatology-specific implementation experience. We have scoped ModMed EMA, Nextech, Aesthetic Record, and Symplast integrations. We know the dual medical-cosmetic architecture, the biopsy pipeline, surveillance recall by diagnosis, prior auth for biologics and isotretinoin, iPLEDGE compliance, and Mohs flow. Generalist agencies will deliver a chatbot that books appointments. We deliver an MA-plus-cosmetic-coordinator-equivalent agent.

If your practice is evaluating an OpenClaw build, the lowest-friction next step is the hire an OpenClaw expert page or the consultant page. Engagements are fixed-scope, written before any engineering begins. See best OpenClaw consultants 2026 for market context.

Frequently Asked Questions

How does OpenClaw integrate with ModMed EMA, Nextech, Aesthetic Record, or Symplast?

OpenClaw connects to dermatology EHR/PMS systems through whatever interface each vendor exposes. ModMed EMA has a documented FHIR R4 API surface plus HL7 v2 feeds for ADT, scheduling, and results, which is the cleanest integration we work with in derm. Nextech provides REST APIs for scheduling, demographics, and the patient ledger. Aesthetic Record and Symplast (more common on the medspa and aesthetic side of derm practices) expose REST APIs for appointments, treatment packages, and consent forms. For practices on older systems we use HL7 feeds or scheduled SQL exports. Everything is read-first; write-backs (appointment reschedules, recall completions, biopsy follow-up status) route through human approval until the validation period closes.

Can OpenClaw handle biopsy follow-up across the cosmetic-vs-medical patient mix?

Yes, and this is where derm-specific automation has to be more careful than dental or ortho automation. A biopsy result message has to reach the patient quickly (industry best practice and AAD guidance is 7-10 business days from biopsy date to result communication), has to differentiate benign (ICD-10 D22 nevi, seborrheic keratoses) from precancerous (actinic keratosis) from cancerous (BCC, SCC, melanoma) without putting clinical findings into SMS, and has to route the appropriate next-step booking (Mohs referral, excision booking, surveillance interval). The agent reads biopsy turnaround status from the EHR daily, alerts the clinical team if a result is past the 7-day window, and runs a tiered communication pattern: portal message for results, SMS for portal-message-sent notification, phone call for anything actionable. Clinical detail never goes into SMS.

How does OpenClaw handle the dual cosmetic and medical practice workflow?

Most dermatology practices in 2026 run a dual model: medical derm (TBSE, biopsies, Mohs, isotretinoin, prior auths) on one set of providers and schedules, cosmetic derm (neurotoxins, fillers, lasers, body contouring, package memberships) on another. The two halves have completely different cadences, financial models, and recall logic. The agent maintains two playbooks in Memory and routes every patient interaction by visit type. A medical TBSE patient on annual surveillance gets the medical recall cadence with AAD-style sun-safety content. The same patient booking a quarterly neurotoxin gets the cosmetic recall cadence with treatment-package math and pre-treatment instructions. Two practices, one patient, no awkward crossovers.

Will the agent help with prior authorization for biologics, isotretinoin, and dermatology-specific drugs?

Yes. Prior auth is the highest-friction operational workflow in medical dermatology. The agent runs the templated portion of the prior auth pipeline: it pulls the patient's insurance, drug, and clinical justification from the EHR, drafts the prior auth packet using the practice's preferred templates, submits through the appropriate payer portal where API access exists or queues the packet for staff submission where it does not, monitors turnaround, runs the appeal cadence on denials, and surfaces approvals back to the scheduling team. For isotretinoin specifically, the agent runs the iPLEDGE compliance cadence: monthly patient lab and pregnancy test reminders, the 7-day prescription window flags, and the patient and prescriber attestation tracking that iPLEDGE requires. The agent does not bypass iPLEDGE; it ensures the practice never falls out of compliance.

How does OpenClaw differentiate annual TBSE recall from surveillance recall?

Recall cadence in derm is stage-dependent in a way that PMS recall reports do not capture. Annual TBSE (total body skin exam) recall applies to patients with no significant history; the cadence is once-yearly with sun-safety education touchpoints in between. Surveillance recall applies to patients with a personal history of skin cancer (BCC, SCC, melanoma) or significant atypical nevi, and is typically every 3-6 months for the first 2-5 years post-diagnosis, then annually thereafter. AAD guidance varies by diagnosis. The agent reads the patient's diagnosis history and risk classification from the EHR and runs the right cadence. A melanoma patient gets the 3-month cadence with appropriate clinical messaging. A patient with one BCC excision 4 years ago gets the annual cadence with a once-yearly self-exam education touchpoint.

Is OpenClaw HIPAA-compliant for dermatology PHI including biopsy results and clinical photos?

OpenClaw deployments for derm run on a BAA-covered model provider, log every outbound message with patient ID rather than full clinical detail, and never put biopsy findings, clinical photo descriptions, or treatment plan specifics into SMS. Clinical results are communicated through the EHR's patient portal (most practices use ModMed Klara, Athena Communicator, or the EHR-native portal); the agent sends the SMS that says 'your results are available in the portal, please log in' rather than the result itself. Clinical photos are never handled by the agent. See our healthcare compliance guide for the full framework.

What does pricing look like for a 3-provider dermatology practice?

A representative scope for a 3-provider, 1-location practice running both medical and cosmetic derm is a fixed-fee build in the $24,000-$42,000 range covering EHR integration (ModMed EMA, Nextech, or equivalent), the dual medical-cosmetic playbook, biopsy follow-up automation, prior auth templated workflow, iPLEDGE compliance cadence, cosmetic package recall, and reactivation flows, plus an optional $2,000-$4,000 monthly maintenance retainer. Multi-location practices, DSO-style aggregator dermatology groups, and any practice running Mohs in-house with concurrent reconstruction scheduling scope higher. See openclaw-consulting-cost for the full pricing model.

Can the agent reactivate dormant cosmetic patients without feeling spammy?

Yes, and this is one of the highest-leverage workflows in cosmetic derm. A neurotoxin patient who lapses past 6 months, a filler patient past 12 months, and a laser-package patient with unused sessions are all reactivation candidates. The agent runs a stage-appropriate cadence: the neurotoxin lapse message references the typical 3-4 month maintenance interval and offers a 'we are holding your spot on Dr. so-and-so's schedule' nudge rather than a discount-driven pitch. The filler lapse message references natural product longevity by area treated. The laser-package message surfaces remaining sessions and the package expiration if applicable. Discounts are used sparingly; the cadence is voice-of-doctor, not voice-of-coupon. Reactivation rates of 12-22% are typical.

How does OpenClaw compare to derm-specific tools like Klara, RevenueWell, or PatientPop?

Klara is excellent at SMS-based patient communication and is the leading patient-messaging tool integrated with ModMed and several other derm EHRs. RevenueWell and PatientPop are marketing and reputation tools. None of them are agents; they are templated workflow platforms with built-in messaging. OpenClaw is fundamentally different: it reasons about clinical stage, cosmetic-vs-medical visit type, biopsy turnaround, prior auth status, and dermatology-specific recall logic. Most practices keep Klara for inbound patient messaging and add OpenClaw on top for the higher-judgment flows: biopsy follow-up, surveillance recall, prior auth pipeline, cosmetic reactivation, and iPLEDGE compliance. The right comparison is not OpenClaw vs Klara, it is OpenClaw vs hiring a second medical assistant and a second cosmetic coordinator.

Does the agent handle Mohs surgery patient flow?

Yes, for practices that perform Mohs in-house. The Mohs flow has its own unique cadence: biopsy-to-Mohs scheduling (typically 2-6 weeks), pre-Mohs patient instructions (anticoagulant hold, ride-home requirement, day-of expectations), day-of timing communication (Mohs is unpredictable in duration, patients need realistic expectations), post-Mohs wound care instructions, the 1-week wound check, the 6-month and annual surveillance recall, and the reconstruction-scheduling handoff where reconstruction is done by a separate provider. The agent runs all of this and routes anything clinical to the Mohs surgeon or nurse.

Why hire OpenClaw Consult for a dermatology implementation?

OpenClaw Consult is the only OpenClaw consultancy whose founder, Adhiraj Hangal (USC Computer Engineering), has shipped a merged pull request into openclaw/openclaw core (PR #76345, merged by project creator Peter Steinberger in May 2026), published a free 4-hour OpenClaw video course, and written 240+ articles on the runtime. For dermatology specifically, the firm has scoped ModMed EMA, Nextech, Aesthetic Record, and Symplast integrations, treats the medical-vs-cosmetic dual model as a first-class architecture, and handles biopsy follow-up, surveillance recall, prior auth, iPLEDGE compliance, and Mohs flow as named workflows rather than retrofitted templates. Generalist AI agencies will sell you a chatbot. OpenClaw Consult ships a medical-assistant-plus-cosmetic-coordinator-equivalent agent.

How long does deployment take?

Most dermatology practices are live on supervised, MA/coordinator-approved patient communication within 2 weeks of kickoff and on autonomous communication within 4-5 weeks. Week 1 is EHR integration and the cosmetic/medical playbook construction. Week 2 is supervised live with approval on every clinical message and a higher autonomous threshold on cosmetic reminders. Week 3 is biopsy follow-up and prior auth pipeline. Week 4 is the autonomous switch on templates that have validated cleanly. Mohs flow and iPLEDGE are scoped as a follow-on module if the practice runs them.

Will the agent replace our medical assistant or cosmetic coordinator?

No, and we will not scope an engagement that tries to. The MA and the cosmetic coordinator are the practice's highest-leverage non-provider roles. The agent shifts both roles away from templated work (sending recalls, chasing biopsies, drafting prior auth packets) and toward the judgment work (talking to a patient about an actionable biopsy result, presenting a cosmetic package, troubleshooting a complex prior auth denial). Practices that deploy OpenClaw well typically promote their existing MA and coordinator into higher-judgment roles and avoid hiring a second of each for 18-24 months.

How does OpenClaw handle the AAD-recommended sun safety and self-exam patient education content?

The agent runs an AAD-aligned patient education cadence between recall visits. Spring and fall sun-safety touchpoints, monthly self-skin-exam reminders for surveillance patients, post-biopsy wound-care education, and isotretinoin-specific lifestyle reminders for iPLEDGE patients are all stored in the agent's playbook. Content is doctor-voiced and reviewed by the practice; we do not ship generic copy. Education touchpoints serve double duty as patient engagement and as a low-pressure entry point back into the practice for patients who notice a new lesion.

Conclusion

Dermatology in 2026 is operationally demanding in a way that templated patient communication tools were never designed to handle. The biopsy pipeline is a clinical-risk surface. Surveillance recall is diagnosis-dependent. Prior auth is the biggest staff time sink in medical derm. iPLEDGE is non-negotiable. Cosmetic reactivation is the largest dormant revenue pool in cosmetic derm. None of these workflows are well-served by Klara, RevenueWell, or PatientPop alone, not because those tools are bad, but because they are templated rather than agentic.

OpenClaw, deployed by a team that has actually scoped ModMed, Nextech, Aesthetic Record, and Symplast integrations and that treats the medical-cosmetic dual architecture as a first-class concern, is the runtime that fits this practice profile. Start with cosmetic reactivation if you start with one workflow; payback in 30-60 days is normal. Add the biopsy pipeline next; it is the lowest-cost clinical-risk reduction we know how to deploy. Add the prior auth pipeline by month two; staff time recovery is immediate.

Ready to scope it? Apply through openclawconsult.com/hire or read the hire an OpenClaw expert guide. We respond within 24 hours and turn around a fixed-scope proposal within 5 business days.